

a<sup>2</sup> 4. (Amended) The method of claim 1 wherein the vessel has at least [one flexible] two walls  
with one wall being more deformable than the other wall.

a<sup>3</sup> 6. (Amended) The method of claim 1 wherein each of the particles [having] has a [mean]  
volume of between about  $5 \times 10^{-24} \text{ m}^3$  to about  $5 \times 10^{-6} \text{ m}^3$ .

7. (Amended) The method of claim 1 wherein the [substantial binding of the] particles  
[results at least in part from the particles having a coating] are coated.

a<sup>4</sup> 10. (Amended) The method of claim 1 wherein the coating comprises a polycationic  
polymer.

12. (Amended) The method of claim 1 wherein the [network comprises] particles comprise a  
primary antibody and the additive comprises a secondary antibody, [where] the primary  
antibody [has] having a substantial binding to [the] a surface component of the cells, and  
the secondary antibody [has] having a substantial binding to the primary antibody.

a<sup>5</sup> 13. (Amended) The method of [claim] any of claims 1 – 12 wherein the cells predominantly  
comprise red blood cells.

14. (Amended) The method of [claim] any of claims 1 – 12 wherein the [sample includes]  
blood cells comprise white blood cells and platelets.

15. (Amended) The method of any of claims 1 – 12, further comprising measuring [PSA]  
prostate specific antigen.

16. (Added) The method of claim 1, further comprising measuring creatinine.

17. (Amended) The method of any of claims 1 – 12 wherein at least 70% by volume of the  
[theoretically available] cell depleted portion is separated from the network within ten  
minutes.

a<sup>6</sup> 21. (Amended) The method of any of claims 1 – 12 wherein at least 90% by volume of the  
[theoretically available] cell depleted portion is separated from the network within ten  
minutes, with a separation efficiency of at least 95%.